The human insulin receptor has two isoforms derived from alternative splicing of exon 11 of the insulin receptor gene. The type B (containing exon 11, or exon 11 + ) isoform binds insulin with twofold lower affinity than the type A (lacking exon 11, or exon 11-) isoform. In efforts to resolve the controversy over whether altered splicing is involved in the development of insulin resistance and non-insulin-dependent diabetes mellitus (NIDDM), the spontaneously obese diabetic rhesus monkey, a unique model that is extraordinarily similar to human NIDDM, was used. Cross-sectional studies of insulin receptor mRNA splicing variants in vastus lateralis muscle were performed on 19 rhesus monkeys. When monkeys were divided into four groups based upon the known stages of progression to NIDDM: normal (normoglycemic/normoinsulinemic), prediabetic (normoglycemic/hyperinsulinemic), early NIDDM (hyperglycemic/hyperinsulinemic), and late NIDDM (hyperglycemic/ hypoinsulinemic), both hyperinsulinemic groups had significantly higher percentages of the exon 11-mRNA splicing variant compared to the normal (74.8±1.7 vs 59.0 ±2.3%; P < 0.005) and late NIDDM groups (74.8±1.7 vs 64.2±3.9%; P < 0.05). Our findings provide the first direct evidence linking hyperinsulinemia to alterations in insulin receptor mRNA splicing, and suggest that alterations of insulin receptor mRNA splicing in muscle is an early molecular marker that may play an important role in NIDDM.
Introduction
Non-insulin-dependent diabetes mellitus (NIDDM)' is one of the most common human diseases, and is characterized by insulin resistance in all major target tissues, especially skeletal mus-cle, as well as ,8-cell dysfunction ( 1, 2) . A number of candidate genes and their protein products that are involved in the pathways leading to insulin action have been implicated as potential molecular defects leading to NIDDM ( 1-6). However, the molecular basis of insulin resistance associated with typical NIDDM remains unknown.
The human insulin receptor gene is a single-copy gene located on the short arm of chromosome 19 , consisting of 22 exons spanning more than 120 kb. It encodes a transmembrane protein consisting of two extracellular a-subunits and two transmembrane /-subunits (a232)-Insulin binds extracellularly, leading to autophosphorylation and activation of the receptor's tyrosine kinase. Subsequent phosphorylation of endogenous substrates leads to some or all of the actions of insulin (5) (6) (7) (8) (9) .
Mutations in the insulin receptor gene have been identified in patients with rare genetic syndromes of extreme insulin resistance (10) . However, these mutations are very rare among patients with the mild to moderate insulin resistance commonly observed in typical NIDDM (11) . Since some studies have shown qualitative or quantitative differences in insulin binding, phosphorylation, or signal transduction in NIDDM, other potential molecular defects in the insulin receptor may be present ( 1, 2, 4, 5) .
The human insulin receptor has two isoforms which are derived from alternative mRNA splicing of the short (36 bp) exon 11. The type B (containing exon 11, or exon 11+) isoform has 12 additional amino acids at the carboxy terminus of the a-subunit, while the type A (lacking exon 11, or exon 11-) isoform does not contain these amino acids (12, 13) . The exon 11+ isoform binds insulin with twofold lower affinity (14) (15) (16) . However, the relative ability of each receptor isoform to transduce downstream events leading to insulin action is less certain (17) (18) (19) (20) (21) . It is appealing to speculate that alterations in mRNA splicing may be responsible, at least in part, for insulin resistance and NIDDM. In fact, others have shown both at the mRNA and protein levels that the exon 11 + receptor isoform is markedly increased in the muscles of subjects with NIDDM, compared with nondiabetic controls (22) (23) (24) (25) (26) . These findings could not be substantiated by other groups (27, 28) . The reason for the discrepancies between studies is unclear, but it may be due to differences in patient and tissue selection, control groups, experimental methods, or other confounding variables. Obvious limitations in all of these studies include difficulty in obtaining samples from multiple tissues in humans and the lack of good longitudinal data.
The spontaneously obese diabetic rhesus monkey is extraordinarily similar to human NIDDM with respect to its clinical presentation and underlying pathophysiology (29) (30) (31) . When maintained in a protective environment and allowed ad lib. access to food, rhesus monkeys frequently develop obesity and insulin resistance, and many of the obese go on to develop diabetes. Longitudinal studies indicate that in monkeys, as in of the same downstream primer that was used for reverse transcription and upstream (sense) primer (5'-TCTGTGCCCCTGGATCCAAT-CTC-3') corresponding to a region within exon 9 of the human insulin receptor gene. 37 cycles of PCR were performed, each cycle consisting of denaturation (1 min at 94°C), annealing (1 min at 65°C), and extension (1 min at 72°C), except that in the first cycle, the denaturation time was increased to 5 min, and in the last cycle the extension time was increased to 10 min.
Cloning and DNA sequence analysis. The expected 640 bp (exon 11-) and 676 bp (exon 11+) PCR products were ligated into pCRII (Invitrogen, San Diego, CA) using established methods. Recombinant plasmids were used to transform competent DH5a Escherichia coli (Bethesda Research Laboratories, Gaithersburg, MD), and transformants were selected on agar plates containing ampicillin and X-gal (5-bromo-4-chloro-3-indolyl-/3-D-galactopyranoside). Plasmid DNA was prepared from colorless colonies (Qiagen, Chatsworth, CA). Dideoxy-sequence analysis was performed using established methods (K/ RT sequencing kit; Promega Corp.). Two independent PCR reactions were performed, and clones from each were sequenced to exclude potential PCR artifacts.
Quantitation of the relative amounts of the two insulin receptor mRNA splicing variants. The relative amounts of mRNA corresponding to the exon 11-and exon 11 + insulin receptor isoforms were determined using RNA template-specific PCR (RS-PCR),' developed in our laboratory. RS-PCR has equal sensitivity to conventional RT-PCR, but dramatically reduces the frequency of false positives (32). Briefly, reverse transcription was performed as described above with primer d,7t30 (5 '-CGTATCAGCAGATCCTAGGAATTCTCGGACTTGTTC ACCACCTTCTC-3') which contains 17 bases at its 3' end (segment d17, underlined) that correspond to a region within exon 12 of the rhesus insulin receptor gene, and a unique 30-base tag (segment t30) at its 5 ' end. The resulting cDNA containing the unique 30-base tag at its 5' end was amplified by PCR with upstream (sense) primer (5 '-CACCAT-TCGAGTCTGAAGATTCTCAGAAGC-3') corresponding to a region within exon 9 of the rhesus insulin receptor gene, and downstream sham Corp., Arlington Heights, IL) was incorporated directly into the PCR product. PCR reaction concentrations and conditions were essentially the same as those described above, except 34 cycles were performed.
The two resulting radiolabeled PCR products differed in size by 36 bp (382 bp versus 346 bp), and were separated on a 6% denaturing polyacrylamide gel. The gel was dried and autoradiography was performed. The relative amounts of the two mRNA splicing variants were quantitated using a beta scanner (Betagen, Waltham, MA). Data were corrected by subtracting background and adjusting for the additional cytosines in the larger (exon 11+) variant. To confirm that the two mRNA splicing variants were being amplified in an unbiased manner, known ratios of the in vitro synthesized RNA corresponding to the two mRNA splice variants were amplified and quantitated.
Statistical methods. The relative amount of the exon 1-(type A) variant was calculated as a percentage of total (exon 11-plus exon 11+), and expressed as the mean+SEM. One-way ANOVA was performed to determine if means were different by groups. Scheffe's S was used to control for multiple comparisons. Differences in regional distribution of the mRNA splicing variants in fat and muscle were determined using a paired t test. Spearman regression was used for correlation analysis. The level of significance accepted was P -0.05.
Results
Characterization of exons 9 through 12 of the rhesus insulin receptor gene. To study insulin receptor mRNA splicing in the spontaneously obese and diabetic rhesus monkey, we first used a PCR-based cloning strategy to obtain a cDNA sequence corresponding to exons 9 through 12 of the rhesus insulin receptor gene. RT-PCR of rhesus liver RNA with primers derived from the human insulin receptor sequence followed by subcloning resulted in two products, 640 and 676 bp in length. Sequence analysis revealed that the longer clone contained exon 11, while the shorter clone lacked exon 11. These findings confirm that like the human, the rhesus monkey has two insulin receptor mRNA splicing variants. The rhesus insulin receptor gene is very similar to human (98.4% nucleotide identity, 99.5% amino acid identity) (7-9), rat (90% amino acid identity) (33) , and mouse (89.9% amino acid identity) (34) in the region studied ( Figs. 1 and 2 ).
Alternate Insulin Receptor mRNA Splicing in Rhesus Muscle 
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RHESUS: TPTSPEEHRP FEKVVNXZSL VISGLRHFTG YRIZLQACNQ 800 Quantitation of the relative amounts of the two insulin receptor mRNA splicing variants. For accurate quantitation of the two insulin receptor mRNA splicing variants, we used RS-PCR, a modified reverse transcription-PCR assay (32). Primers were designed that flanked the exon 11 splice junctions (Fig. 3 A) . To determine if the two mRNA splicing variants were being amplified in an unbiased manner, a validation experiment was performed. In vitro synthesized rhesus insulin receptor RNA containing or lacking exon 11 were mixed in varying ratios, and RS-PCR was performed (Fig. 3 B) . The PCR product output ratios were virtually identical to the RNA input ratios (r = 0.999) confirming that the two mRNA splicing variants were being amplified in an unbiased manner (Fig. 3 C) . A cycle titration revealed that 34 cycles was within the logarithmic phase of amplification (data not shown).
Tissue-specific expression of the two insulin receptor mRNA splicing variants in the rhesus monkey. To discern the relative amounts of the two insulin receptor mRNA splicing variants in various tissues, RS-PCR was performed from RNA extracted from rectus abdominis muscle, intraabdominal fat, liver, stomach, heart, kidney, brain, and spleen of monkeys ranging from normal to NIDDM (Fig. 4) . The 11-variant (12, 13, 33) .
Regional distribution of insulin receptor mRNA splicing Cross-sectional analysis of insulin receptor mRNA splicing variants in muscle ofnondiabetic and diabetic rhesus monkeys.
To determine whether there are alterations in the relative amounts of the two insulin receptor mRNA splicing variants between nondiabetic and diabetic rhesus monkeys, the relative amounts of the exon 11-and exon 11 + receptor mRNA variants were determined in the skeletal muscle (vastus lateralis) from 19 monkeys which were at different stages ranging from normal to overtly diabetic (Table I) . Measurement of the relative amounts of the two insulin receptor mRNA splicing variants revealed that there were no differences between normoglycemic and diabetic monkeys (Fig. 6 A) (Fig.  5 ). These findings may be due to intrinsic differences in the relative amounts of the two mRNA splicing variants in the myocytes themselves, perhaps relating to the proportion of slow and fast twitch fibers (36) . Alternatively, these differences may be due to differences in the amount of intramuscular fat tissue present in the respective muscle regions.
Our studies in rhesus monkeys show that the relative amounts of the two insulin receptor mRNA splicing variants parallel circulating insulin levels, and not glycemia (Fig. 6 B  and C) . Thus, monkeys that are hyperinsulinemic (prediabetic or early NIDDM) have higher amounts of the exon 11-mRNA splicing variant than monkeys that are not hyperinsulinemic (normal or late NLDDM) (Fig. 6 D) .
These studies may provide an explanation for the discrepancies reported by different groups. For example, the observations of Mosthaf et al. (22) and Kellerer et al. (23) , that diabetic subjects have less of the exon 11-mRNA variant, may be explained if they were comparing normoglycemic subjects with high insulin levels (this study's prediabetic group) to diabetics (this study's late NIDDM group) (Fig. 6 B) . Similarly, the observations of. Benecke et al. (27) and Hansen et al. (28) , that there were no differences in alternate splicing variants between nondiabetic and diabetic subjects, could be explained if they were comparing normoglycemic subjects (this study's normal and prediabetic groups combined) with diabetic subjects (this study's early and late NIDDM groups combined) (Fig. 6 A) .
Insulin resistance and hyperinsulinemia, even in the presence of normoglycemia, are risk factors for developing NI1DDM
in both humans (37) (38) (39) and monkeys (30 (23, 27) .
Since the biological properties of the two insulin receptor isoforms are poorly understood, it is unclear whether alterations in their expression early in the course of developing diabetes is a primary defect or a secondary change due to hyperinsulinemia. If the exon 11-isoform, which has twofold greater binding affinity and better internalization, also has greater ability to mediate insulin's metabolic effects, the early increase in the relative amount of the exon 11-isoform might lead to an increase in sensitivity that may be compensatory for a postreceptor deficit in insulin action. Later in the progression to diabetes, ,6 cell dysfunction leads to hypoinsulinemia, and a relative decrease in the amount of the exon 11-isoform. This decrease may contribute to worsening of apparent insulin action later in the course of the disease.
Alternatively, if some of the metabolic actions of insulin are transmitted better by the exon 11 + isoform as reported by Kellerer et 
